Noelle Callizot, CSO
Founded in 2013, Neuro-Sys is a well-established contract research organization (CRO) specializing in pharmacology and drug development. As a pioneer in the neurodegenerative market, Neuro-Sys develops advanced pre-clinical in vitro models for assessing Central Nervous System (CNS) and Peripheral Nervous System (PNS) disorders. The company has developed specific pre-clinical models of neurological diseases to accurately determine the lead compounds’ pharmacological profiling and explore their underlying action mechanism. With such an approach, Neuro- Sys aims at improving pharmacology efficacy in the market.
The company has dedicated researchers including best-in-breed physicians, neurologists, and scientists with pharma and biotech background, who run in-house R&D programs to identify and develop new compounds. Backed by a competent workforce, Neuro-Sys is adept at supervising every step of the pharmaceutical development process and proves to be a reliable advisor to its clients.
Neuro-Sys runs numerous science and research programs to decode the reasons behind a neuron’s progressive loss of structure or function. Based on the results, the firm formulates a detailed plan to develop robust, relevant, and efficient pre-clinical models for neurodegenerative diseases. However, prior to modeling the drugs, Neuro- Sys helps its clients in designing and developing pre-clinical and clinical plans to identify leading compounds and even find some new leads. The models are then formulated based on the newfound compound or molecule. “Our ability to develop medical models that mimic the pathology of different diseases such as Alzheimer’s or Parkinson’s is unrivalled and exceptional,” mentions Noelle Callizot, CSO at Neuro-Sys.
Moreover, Neuro-Sys also holds expertise in the development of innovative models by leveraging its world-class, high-level scientists and high-end laboratory equipment.
Our ability to develop medical models that mimic the pathology of different diseases such as Alzheimer’s or Parkinson’s is unrivalled and exceptional
“By screening the pre-clinical models, we better understand how compounds work and what could be the therapeutic area where we could help develop compounds for specific diseases,” mentions Noelle. Altogether, within its drug development services, the firm defines the compound’s mode of action, designs and selects the best vivo investigations, conducts toxicological studies, and ensures regulatory and non-regulatory requirements.
As a part of its portfolio, the company offers fully automatic pharmacological platforms to screen in vitro and in vivo pre-clinical and pharmacological assays. Additionally, Neuro-Sys studies the developed models on these platforms to eliminate the errors instances in the drug development process.
For years, Neuro-Sys has assisted multiple organizations across the globe in their drug development process. Among many use cases, the firm preferred to highlight a client interaction as an example. A biotech company that was developing compounds for Parkinson’s disease (PD) under a targeted time frame contacted Neuro-Sys for help. Being a neurodevelopment expert, Neuro-Sys proposed a detailed plan on performing specific screening assay for PD indication. Initially, the firm screened thousands of molecules and selected around 50 different molecules. Thereafter, Neuro-Sys scrutinized those 50 molecules to find the best molecule with maximum efficacy level and minimum side effects. Lastly, the company conducted the final screening on the blood-brain barrier (BBB) and chose molecules with powerful brain penetration. “We were able to select three distinct leading compounds for the client and enabled them to proceed with vivo selection and all the regulatory requirements, we are now close to enter in patient clinical development with a candidate molecule,” explains Noelle.
The company is now moving forward with a plan to expand its screening platform and the laboratory’s size, with a vision to improve the number of different models. Neuro-Sys also envisions improving the precision of its models, mimic the pathologies’ characteristics as accurately as possible, and be as real as possible. “We have many projects lined up and our aim is to provide the best service for pharmacology and neurodevelopment,” concludes Noelle.